Orexigen Therapeutics, a San Diego-based biopharmaceutical company focused on obesity treatment, has announced the upcoming departure of Graham Cooper, its chief financial officer and treasurer.
Cooper has been with the company for more than four years. A press release indicated he is leaving for personal reasons. He will leave the company after reporting year-end results and filing the company’s annual report on Form 10-K with the Securities and Exchange Commission.
Orexigen plans on appointing Jay Hagan, its corporate development and strategy senior vice president, as acting CFO. Hagan has been with Orexigen since May 2009.
Topic: